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A B S T R A C T   
Traumatic brain injury (TBI) is characterized by a complex network of signals mediating inflammatory, prolif-
erative and apoptotic processes during its acute and chronic phases. Current therapies mitigate damage and are 
mainly for palliative care and there are currently no effective therapies for secondary damage. This suggests a 
need to discover a compound with a greater spectrum of action that can control various pathological aspects of 
TBI. Here we used a network pharmacology approach to explore the benefits of tibolone, an estrogen and 
androgen receptor agonist with broader actions in cells, as a possible repurposing drug for TBI therapy. Using 
different databases we retrieved the targets significantly associated to TBI and tibolone, obtaining 2700 and 652, 
respectively. The top 10 GO enriched terms were mostly related to cell proliferation, apoptosis and inflammation. 
Following protein-protein functional analysis, the top connected proteins were related to kinase activity 
(MAPK1/14/3, AKT1 PIK3R1), apoptosis (TP53, CASP3), growth factors (EGFR), estrogen signalling (ESR1) and 
inflammation (IL6, TNF), with IL6 as an important signalling hub belonging to the top GO categories. Thus, we 
identified IL6 as a cellular node which we then validated using molecular mechanics-generalized born surface 
area (MMGBSA) and docking to explore which tibolone metabolite might interact with this protein. Both 3α and 
3β-OH tibolone seemed to bind better to IL6 at important sites responsible for its binding to IL6R. In conclusion, 
our study demonstrates key hubs involved in TBI pathology which indicates IL6 as a target molecule of tibolone 
as drug repurposing for TBI therapy.   
1. Introduction 
Traumatic brain injury (TBI) is one of the leading causes of death 
worldwide. Traffic accidents, falls and domestic traumas generate long- 
lasting disabling conditions for those who suffer, generating not only a 
great burden for the public health systems as well as financial con-
straints since it mostly affects people at their productive age. TBI’s 
pathological mechanism involves two phases, acute and chronic, where 
inflammation is a common feature in both phases with the active 
participation of glial cells having serious impact over neuronal popu-
lation in the long run. Unfortunately, there is no cure to fight TBI, cur-
rent therapeutics target only the symptoms or one sole mechanism of its 
pathology, demonstrating the utterly urgent need to search for com-
pounds with broader spectrum of actions that could mitigate post-TBI 
inflammation. 
The therapeutic broad actions of androgens and estrogens on TBI has 
been long investigated [1–6]. Estradiol and its precursor, testosterone, 
promote synaptic and axonal regeneration [7–12], induce the expres-
sion of antiapoptotic molecules in neurons [13,14] and protect neurons 
against various cellular stressors [15]. More specifically, by regulating 
reactive glia testosterone and derivatives, dihydrotestosterone (DHT) 
and estradiol, after penetrating brain injury indicates a promising 
anti-inflammatory potential [16]. In a similar fashion, estradiol also 
regulates astrogliosis in TBI animals via cannabinoid signalling [17]. 
Much of the benefits of estradiol on TBI may be related to its ability to 
reduce the levels of cytokines IL6, TNF-α, IL-1β, among others, all 
upregulated in TBI, which could explain a significant reduction in the 
number of reactive astrocytes and microglia after brain injury [18–21]. 
Despite the benefits offered by therapy in TBI with these hormones, 
long-term therapeutics is limited by the possible risk of developing 
tumoural processes in certain tissues [22]. Consequently, the need to 
explore drugs that preserve the beneficial role of estrogens in the brain, 
but without the negative impact they have on other tissues, is highly 
desirable. 
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One FDA-approved drug with potential clinical use in TBI is tibolone. 
Tibolone, a selective tissue estrogenic activity regulator (STEARs), is a 
synthetic steroid in current clinical use by postmenopausal women to 
reduce menopause symptoms. When metabolized, it gives rise to three 
metabolites, 3α-OH-tibolone and 3β-OH-tibolone, both acting on estro-
gen receptors alpha (ERα) and beta (ERβ), thereby exerting estrogenic 
actions over the brain, and Δ4-tibolone with binding preference for both 
progesterone and androgen receptors [23]. In 2007, Guzmán et al. 
described for the first time the effects of tibolone metabolites on glial 
cells [24], and more recently our group has reported astrocytic and 
microglia cells in vitro have improved cell survival, reduced oxidative 
damage and preserved mitochondria integrity when exposed to 
inflammation by glucose deprivation [25,26] and toxic levels of satu-
rated fatty acids [27–32], being much of tibolone’s action mediated by 
ERβ. Furthermore, tibolone exerted anti-oxidative properties in ovari-
ectomized rats fed with high fat diet [33] and after ozone exposure [34, 
35]. Using an in vivo model of TBI, similarly to estradiol benefits, 
tibolone regulated the number of GFAP+ astrocytes and iba1+ microglia 
bordering the wound injury and that correlated with improved neuronal 
survival following penetrating brain injury [36]. Altogether, these 
studies suggest repurposing tibolone for use in TBI could work. Despite 
this promising therapeutic action of tibolone in reducing inflammation 
and glial response to brain trauma, little is known about what other 
signalling pathways being regulated by this drug could be considered as 
critical druggable targets for future pharmacological exploitation. In the 
present study, we applied the concept of network pharmacology to un-
ravel correlations between proteins, pathways, and genes being regu-
lated by tibolone and those involved in TBI pathology. Our main aim 
was to integrate and elucidate the complex mechanisms of actions of 
tibolone on TBI. 
2. Materials and methods 
2.1. Identification of tibolone targets 
For this study, we used the SMILEs of tibolone metabolites 3α-OH 
tibolone, 3β-OH tibolone, and Δ4-tibolone for the prediction of possible 
molecular targets using the databases SEA (https://sea.bkslab.org/), 
Targetnet (http://targetnet.scbdd.com) and SwissPrediction (http://s 
wisstargetprediction.ch), which is a comprehensive database that 
based on similarity it predicts the targets of each compound. As inclu-
sion criteria we limited our search to “Homo Sapiens” and a probability 
greater than 0.05. Additionally, using the CTD (http://ctdbase.org) and 
DrugBank (https://www.drugbank.com) databases with search term 
“Tibolone” we identified the proteins and enzymes modulated by this 
drug. Afterwards, the data was combined, duplicates eliminated, and 
finally using Uniprot (https://www.uniprot.org/) we proceeded to unify 
the genes IDs to homogenize the nomenclatures and avoid false 
duplicates. 
2.2. Identification of targets known to be altered or regulated in traumatic 
brain injury 
For the identification of TBI-related targets, we used three databases. 
One is the CTD, a free available database, together with OMIM (https:// 
omim.org/) and Genecard/Malacards (https://www.malacards.org/) 
databases we used the search terms "Traumatic brain injury" and 
"Human", "Homo Sapiens" to collect a list of targets that can be altered or 
participate directly or indirectly in the pathophysiological mechanism of 
TBI. 
2.3. Gene function and Gene Ontology (GO) pathways enrichment 
Gene/protein enrichment and biological annotations were per-
formed using DAVID v6.8 (https://david.ncifcrf.gov/). The common 
genes between TBI and tibolone groups were imported to the database, 
which is a comprehensive and free database that provides full annota-
tion of targets into molecular function, cellular compartment, and 
biology process. For this study we used both GO analysis and KEGG 
pathway annotations to perform the analysis, top 10 in each category 
were filtered out and selected for further analysis. As inclusion criteria a 
p value of 0.05 was selected. All results were graphed using Graphpad 
v9. 
2.4. Protein-protein interaction (PPI) network 
The common genes in TBI and tibolone were imported to cytoscape 
and for the PPI and topological analysis we used two plugins, String and 
Genemania. Both provide predictable protein-protein interactions 
within a network with a confidence ratio of at least 0.5. We used the 
“Analyze network” plugin to determine the degree of confidentiality and 
importance of protein interaction pathways based on parameters such as 
betweenness, degree of interactions, and closeness to identify potential 
hubs within the network that could be considered as pharmacological 
targets of tibolone in TBI. 
2.5. In silico molecular simulation 
To validate the results, we used molecular docking to better under-
stand the interaction between tibolone metabolites and target selected. 
2.5.1. Molecular structure of tibolone metabolites and IL6 protein 
For in silico analysis, we used Molecular Operating Environment 
(MOE 2015) software for molecular docking, after which results were 
validated by SwissDocking (http://www.swissdock.ch/) and Autodock 
Vina in PyRx. For the 2D and 3D analysis we used Discovery Studio and 
Schrodinger Suite 2020, respectively, as well as for the calculation of 
MMGBSA. The 3D structure of the compounds, 3α-OH tibolone (CID: 
10087021), 3β-OH tibolone (CID: 49839851), Δ4-tibolone (CID: 
22814761) were downloaded from Pubchem database (https://p 
ubchem.ncbi.nlm.nih.gov/). 
2.5.2. Protein preparation 
The 3D structure of the human IL6 protein was downloaded from the 
Protein Data Bank (PDB ID: 1ALU). The crystal structure has 186 amino 
acids, a single A chain, and was obtained by X-ray diffraction with a 
resolution of 1.97 A, was processed to eliminate ligands and associated 
ions using MOE, being subsequently protonated and minimized with the 
same software. 
For docking, the MOE dock setting (20,000 different poses for a final 
refinement of 10) was configured. To determine the best conformations 
of the different poses, we used the scores London dG and GBVI/WSA dG, 
which is an estimate of binding energy based on the force field from a 
pose between the ligand and the protein. The five best binding poses for 
each molecule were further analysed. Validation of docking poses was 
assessed using Autodock Vina on PyRx software. The best poses were 
screened, scored and selected for MMGBSA studies. 
2.5.3. Binding free energy (MMGBSA) 
For the calculations of free binding energy of docked complex we 
used the prime module of Maestro 12.5 (Schrödinger, LLC, New York, 
USA) that measures the mechanics-generalized born surface area 
generalized (MMGBSA), using the OPLS3 force and VSGB solvation. 
3. Results 
3.1. Prediction and integration of the molecular targets of tibolone 
metabolites and TBI 
Fig. 1 depicts the workflow used to carry out this study. Initially 
using the SMILES of each tibolone metabolite, we predicted the possible 
targets using Swissprediction, SEA, CTD, and Targetnet, which are 
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databases that use algorithms to identify possible proteins or genes that 
can be modulated by the compounds based on their structural similarity. 
With respect to the metabolite 3α-OH tibolone and 3β-OH tibolone, we 
obtained 100 related genes in SwissPrediction, 4 genes in SEA and 616 in 
Targetnet. For Δ4-tibolone, we obtained 100 in Swisstarget, 22 in SEA 
and 616 in Targetnet. 
Finally, for tibolone, we performed a search using the key terms in 
CTD and Drugbank to explore its downstream actions specifically on 
proteins and enzymes, obtaining 23 and 5 genes, respectively. To 
identify TBI targets, 1586 known were predicted from CTD, 191 from 
OMIM and 1742 in Genecard / Malacards. Duplicated genes were 
eliminated and, finally, using a Venn diagram we compared the target 
genes of TBI and tibolone metabolites (3α, 3β and Δ4-tibolone) showing 
that a total of 301 (9.9%) shared common genes in both groups (Fig. 2) 
and we considered these as potential targets for further analysis. 
3.2. GO enrichment and pathway assessment 
The 301 targets identified as common between TBI and tibolone 
(Suppl. Table 1) were submitted for functional annotation using DAVID 
6.8, which is a public database that aims to correlate the function of 
proteins to a functional category, highlighting their involvement in a 
cellular function with predictable cellular localization. Furthermore, 
this web-based software retrieves information on the number of targets 
belonging to each of these categories and assigns a p-value to determine 
their degree of importance for a particular category. When submitting 
the 301 genes, detailed information on biology process was generated 
with a total of 789 components, cellular compartments (113) and mo-
lecular function (209), with which we selected the top 10 for each 
category and filtered each according to p value or the number of genes in 
each GO term. 
Within the top 10 for Biology Process category, the proteins in 
common between TBI and tibolone actively participate in processes such 
as positive regulation of cell proliferation, which is followed by response 
to drug, negative regulation of apoptotic processes, positive regulation 
of cytosolic concentration of Ca2+, phospholipase C-activating G-protein 
coupled receptor signalling, protein phosphorylation, response to lipo-
polysaccharide, response to inflammation and finally of serine and 
proteins phosphorylation (Fig. 3A). In a very similar way, the largest 
number of proteins participate in proliferative processes (54), signal 
transduction mechanisms (54), negative regulation of apoptosis (46), 
followed by other processes such as regulation of transcription, 
involvement of G-protein coupled receptors, and inflammatory response 
and proteolysis (Table 1). 
GO analysis using DAVID indicated that the top 10 proteins for GO 
Cellular compartment are located either in plasma membrane or are part 
of it as an integral component, followed by cell surface, membrane rafts, 
dendrites or they make part of more specific cells, such as neurons, and 
Fig. 1. Workflow detailing the schematic step-by-step processes carried out in the study.  
Fig. 2. Venn diagram showing the 301 genes in common between TBI and tibolone targets.  
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lastly cytosol as a possible cell location, this one having the lowest p 
value in relation to the top 1 of the list (plasma membrane) (Fig. 3B). 
Similarly, the largest number of proteins (170) is located in or make part 
of the plasma membrane (119), followed by those located in the cytosol 
(111), nucleus (108) and finally at the bottom cell surface with only 47 
genes (Table 1). 
Finally, the top 10 for GO Molecular function according to p value 
included drug binding, followed by enzyme binding, protein kinases 
binding and activities, steroid hormone receptor binding and finally 
RNA polymerase II transcription factor activity (Fig. 3C). Taking into 
account the number of genes in each term for this category (Table 1), 
protein binding is observed as the one containing the largest number of 
targets (228), followed by ATP (72) and enzyme binding (40), protein 
kinase activity (38) and zinc ion binding (38). 
3.3. Construction of protein-protein interaction network 
After having functionally characterized the 301 targets, these were 
imported into cytoscape for PPI network construction. For this analysis 
we used the plugins String and Genemania in cytoscape, both having 
“homo sapiens selected” as organism. For the nodes in both networks, 
we applied the “analyze network” tool in cytoscape to identify those 
targets with the greatest interaction and determine the importance of 
each within the network. 
The network constructed using String on cytoscape contained 301 
nodes, 5769 edges with an average number of 38,400 neighbours 
(Fig. 4). Noteworthy, out of 301 proteins, AKT1 (179), IL6 (154), 
MAPK3 (154), TP53 (136), TNF (136), SRC (125), CASP3 (124), EGFR 
(123), APP (121) and MAPK1 (121) are the top 10 proteins presenting a 
high degree (Table 2), an indicative of the number of predictable in-
teractions. Interestingly, this cluster of proteins also presented a greater 
betweenness and closeness, making them promising hubs in the 
network. 
PPI analysis using Genemania on cytoscape showed more informa-
tion about the network, revealing that 32.09% proteins are making 
physical interactions, while 4.73% shared protein domains and finally 
2.32% shared same pathways. In contrast to String, Genemania 
retrieved a total of 321 nodes, 14,387 edges with an average number of 
70,380 neighbours. Out of 301 proteins and associated interactions, 
MAPK1 (211), MAPK14 (208), PI3KR1 (196), EGFR (195), MAPK3 
(188), FN1 (184), JUN (180), SRC (174), ESR1 (168), and AKT1 (164) 
showed high degree (Table 3). When analysing betweenness (a measure 
of how centralized a node is vs the number of paths crossing it) top 
scored proteins were FN1, followed by APP, PRKCE, EGFR, MAPK14, 
JUN, PIK3R1, OPRD1, MAPK1, and MAPK3. Most of these proteins also 
shared greater closeness (a measure of shortest paths, denoting a better 
flow of information) values (FN1, MAPK1, EGFR, MAPK14, PIK3R1, 
APP, MAPK3 and JUN) and top 10 also included CXCR4 and OPRD1. 
Overall, considering these results, the proteins FN1, MAPK1, MAPK14, 
EGFR, PIK3R1, MAPK3 and JUN are potential hubs in this interaction 
network. 
By comparing top GO categories by DAVID and PPI from String and 
Genemania, we observed that most GO terms and proteins interactions 
fall within the broad categories of inflammation, proliferation, and 
apoptosis/ Ca2+ signalling. Using the list of top proteins in PPI obtained 
from cytoscape we came across that IL6 is the main protein participating 
in all these cellular processes. To explore further IL6 signalling we built a 
subnetwork to identify the closest and direct neighbours of this protein 
(Fig. 5). Interestingly, these include, among others, proteins related to 
steroid hormone activity (ESR1, AR, PPARG, SRC), and regulation of 
cellular metabolic, proliferation and inflammatory processes (F2, AKT1, 
ERBB2, BCL2L1, NOS3, MAPK14, RELA, TP53, TNF, MAPK3, MAPKQ, 
SRC, PIK3CA, PTGS2, EGFR, APP, SIRT1, MMP9, CASP3, CXCR4). 
Fig. 3. Functional analysis and GO enrichment using DAVID6.8. (A) Biology 
process. (B) Cellular compartment. (C) Molecular function. 
Table 1 
Top 10 GO terms using DAVID according to the number of genes.  




positive regulation of cell 
proliferation  
54  6.5  
signal transduction  54  2.6  
negative regulation of apoptotic 
process  
46  5.6  
positive regulation of transcription 
from RNA polymerase II promoter  
46  2.6 
Biology process response to drug  45  8.3  
protein phosphorylation  42  5.1  
G-protein coupled receptor 
signaling pathway  
41  2.5  
inflammatory response  38  5.6  
proteolysis  33  3.7  
positive regulation of 
transcription, DNA-templated  
32  3.5  
plasma membrane  170  2.5  
integral component of membrane  119  1.4  
cytoplasm  111  1.3  
nucleus  108  1.2 
Cellular 
compartment 
cytosol  100  1.8  
integral component of plasma 
membrane  
93  4  
nucleoplasm  75  1.6  
membrane  73  2  
extracellular exosome  64  1.4  
cell surface  47  5.3  
protein binding  228  1.5  
ATP binding  72  2.7  
enzyme binding  40  6.7  
identical protein binding  39  2.9 
Molecular 
function 
protein kinase activity  38  5.9  
protein homodimerization activity  38  2.9  
zinc ion binding  38  1.8  
protein serine/threonine kinase 
activity  
36  5.4  
protein kinase binding  30  4.5  
serine-type endopeptidase activity  26  5.7  
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Because IL6 seems to be an important hub in our network, using in silico 
simulation we next explored which tibolone metabolite might interact 
with IL6, as a possible novel mechanism of its actions in TBI. 
3.4. In silico docking simulation 
For this study, we explored the hypothesis that one of the metabolites 
of tibolone may be able to interact with IL6, which could predict a new 
mechanism of action for this drug. To do this, we performed a molecular 
simulation/docking using MOE software, under standard procedures, 
where we evaluated approximately 20,000 different poses to determine 
the best conformations of 3α, 3β and Δ4-tibolone with the human pro-
tein IL6. Docking analysis showed that 3β-OH tibolone had the best 
binding energy to IL6 (− 6.26 kcal/mol), interacting through residues 
Asp160, Trp157, Lys46, Arg104, Ser107. This was followed by Δ4- 
tibolone (− 5.68 kcal/mol) binding to residues Lys46, Arg104, Trp157, 
Met49 and finally, and in a very similar way to Δ4-tibolone-IL6 complex, 
3α-OH tibolone (− 5.61 kcal/mol) interacted though residues Glu93, 
Pro65, Lys86, Lys66 (Table 4 and Fig. 6A–F). Docking results were 
validated using Swissdocking and Autodock Vina in PyRx. 
To confirm and validate these interactions, we calculated the 
MMGBSA, which is a parameter that identifies the free binding energy 
and the contribution of each ligand and receptor independently and 
combined, then the energy of each type of binding, these being h-bonds, 
Van der Waals (vdw), covalent, and solvent. From MMGBSA results 
(Table 5) there is a slight preference of 3β-OH tibolone to binding IL6. 
The free binding energy of IL6 in complex to 3β-OH tibolone was slightly 
more negative (− 31.16 kcal/mol) than that of 3α-OH tibolone 
(− 29.83 kcal/mol) and much lower than Δ4-tibolone (− 18.92 kcal/ 
Fig. 4. Protein-protein network of genes using cytoscape. String database de-
picts the protein-protein interaction (PPI) among the 301 genes involved in TBI 
pathology and targets of tibolone. 
Table 2 
Top 10 proteins according to the number of degree (interactions) obtained using 
String and analyze network in cytoscape.  
Gene name Degree BetweennessCentrality ClosenessCentrality 
AKT1  179  0.072501998  0.713603819 
IL6  154  0.052654072  0.670403587 
MAPK3  154  0.047961858  0.670403587 
TP53  136  0.0364241  0.645788337 
TNF  130  0.028800007  0.636170213 
SRC  125  0.024802609  0.628151261 
CASP3  124  0.018458671  0.628151261 
EGFR  123  0.028250424  0.626834382 
APP  121  0.042262149  0.624217119 
MAPK1  121  0.02150117  0.622916667  
Table 3 
Top 10 proteins from PPI according to number of degree (interactions) using 
Genemania and analyze network in Cytoscape.  
Gene name Degree Betweenness Centrality Closeness Centrality 
MAPK1  211  0.006689359  0.621359223 
MAPK14  208  0.007272385  0.618955513 
PIK3R1  196  0.006973316  0.617760618 
EGFR  195  0.007856151  0.618955513 
MAPK3  188  0.006608521  0.616570328 
FN1  184  0.009657008  0.628683694 
JUN  180  0.007180673  0.614203455 
SRC  174  0.005162099  0.598130841 
ESR1  168  0.0066006  0.607210626 
AKT1  164  0.005502078  0.587155963  
Fig. 5. IL6 cluster showing the direct neighbors within the protein-protein 
interaction (PPI) subnetwork. 
Table 4 
In silico simulation of tibolone metabolites and IL6 human protein.  
Molecule Binding affinity (Kcal/ 
mol) 
Interacting amino acids 
3α-OH 
tibolone 
-5.61 Glu93, Pro65, Lys86, Lys66 
3β-OH 
tibolone 
-6.26 Asp160, Trp157, Lys46, Arg104, 
Ser107 
Δ4-tibolone -5.68 Lys46, Arg104, Trp157, Met49  
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mol). These results also indicated there was not a significant difference 
in the binding affinity of both 3α and 3β-OH tibolone to IL6, but clearly 
showed that Δ4-tibolone has weaker binding towards IL6 than the es-
trogenic metabolites of tibolone. 
4. Discussion 
In order to explore the molecular targets playing a role in TBI pa-
thology, and those regulated by tibolone, in the present study we delved 
into the possible targets in common and predicted the interaction be-
tween them using a pharmacology network approach to identify the key 
cellular hubs that may serve as potential druggable targets. We identi-
fied 301 genes which are both regulated by tibolone and in TBI and upon 
further analysis identified IL6 as an important hub involved in cell 
proliferation, inflammation, control of apoptosis and Ca2+ regulation 
according to our GO enrichment analysis (Fig. 3). We also found that the 
metabolites of tibolone (3α-OH tibolone, 3β-OH tibolone and Δ4-OH 
tibolone) interacted with several amino acids present in IL6 protein 
(Fig. 6), essential for transducing signalling via IL6R. Together this in-
dicates that an interaction between tibolone and IL6 may contribute to a 
potential therapeutic mechanism of action of tibolone for TBI. 
4.1. Tibolone and IL6 regulation of proliferative and apoptotic cell fates in 
TBI 
Tibolone may activate multiple neuroprotective responses through 
the regulation of signals such as Ca2+ levels, mitochondrial integrity, 
and apoptosis [26–30,37–40] which could be exerting an effect on cell 
proliferation and apoptosis regulation in TBI. Previous studies have 
shown that a penetrating injury not only induces a reactive phenotype in 
astroglia and microglia, but also causes an increased proliferation of 
these glial cells in the vicinity of the wound [41,42]. Interestingly, our 
GO results showed that the top 10 Biology Process category was the 
positive regulation of proliferation and negative regulation of apoptotic 
processes (Fig. 3). In fact, in the penumbra of the wound in TBI, astro-
cytes, for instance, proliferate, and express proteins of the cell cycle, 
such as cyclin D1 and cdk4 kinase [43] and both are sensitive to changes 
in cycle progression. Upon brain injury, there is an increase in cell 
proliferation [44] and reactive astrocytes express both proliferation 
markers (PCNA) and cell cycle proteins [45]. A similar effect could be 
exerted by tibolone in TBI. For example, when rising Ca2+ levels mul-
tiple cellular processes, including calcineurin, cytochrome C, caspase 3 
and the production of free radicals, increase oxidative damage which 
may stimulate apoptosis. In this regard, tibolone negatively regulates 
cytosolic Ca2+ levels in stressed astrocytes [37], while upregulating 
anti-apoptotic Bcl-2 [40] and reducing pro-apoptotic soluble Fas [39], 
suggesting a regulation of programmed cellular death which may have a 
significant positive impact on proliferation. On the other hand, 
following a stab wound injury, ovariectomized female mice given tibo-
lone had less GFAP-positive astrocytes, IBA-1-positive microglia, and a 
reduced number of microglia with an activated morphology [46]. 
Together this suggests that although our results showed a positive 
relationship between tibolone and proliferation in TBI, tibolone may 
reduce the number of glia via another pathway independent of 
proliferation. 
Our study shows that IL6 may also be involved in cellular prolifer-
ation. In vitro studies have shown that IL6 more than likely promotes the 
genesis of astrocytes but in combination with other signalling pathways 
[47,48]. However, IL6 certainly promotes the genesis of microglia. In 
multiple sclerosis IL6 is involved in the T-cell proliferation and infil-
tration process via VCAM-1. In fact, IL6 deficient mice do not develop 
autoimmune symptoms. It has previously been shown that IL6 signalling 
can be simultaneously induced in astroglia and inhibited in microglia 
[49], suggesting that astroglia and microglia have individual regulatory 
mechanisms in response to cytokines such as IL6. 
4.2. Impact of tibolone on post-TBI inflammation 
The anti-inflammatory and antioxidant actions of tibolone are well 
known. Because tibolone is a drug in use by postmenopausal women, 
pro-inflammatory cytokine markers increase in the absence of estrogen, 
especially IL1, IL6 and TNF-alpha [50]. This phenomenon appears to be 
a consequence of reduced circulating estrogen levels and this has been 
alluded to in preclinical and clinical studies [51,52]. In fact, the absence 
of estrogens availability to regulate the anti-inflammatory pathways, it 
appears that anti-inflammatory cytokines such as IL4, IL10 and IL12 are 
upregulated to compensate [53]. This is confirmed by Abdi et al. whom 
identified through a systematic review that hormone replacement 
Fig. 6. In silico simulation of tibolone metabolites and human IL6. 3D and 2D 
representations of IL6 in complex with 3α-OH-tibolone (A, B), 3β-OH-tibolone 
(C, D) and Δ4-tibolone (E, F). 
Table 5 
Free binding energy calculation using MMGBSA.  
Molecule MMGBSA dG_Bind dG_Bind_Coulomb dG_Bind_Covalent dG_Bind_Hbond dG_Bind_Lipo dG_Bind_Solv_GB dG_Bind_vdW 
3α-OH tibolone -29.83285469 -10.3949151 1.354976355 -1.17180571 -6.64314  14.28403 -27.262 
3β-OH tibolone -31.16245322 -13.7020191 1.292942941 -1.72983891 -6.77495  12.81138 -23.06 
Δ4-tibolone -18.92003332 6.967053939 -0.0951789 -0.11890612 -5.26545  9.428573 -29.8361  
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therapies in postmenopausal women reduced the concentration of IL2, 
IL6 and partially reduced the concentration of IL1 [54]. Previous studies 
have shown that tibolone regulates astrocytic phagocytosis [38], pre-
serves astrocytic morphology complexity and mitochondrial integrity 
[28,29]. A similar outcome was observed using an in vitro obesity model 
with palmitic acid when tibolone has shown to attenuate both lip-
otoxicity and the expression of IL6 [29,32], and by acting on ERβ tibo-
lone upregulates neuroglobin – together this reduces the production of 
reactive oxygen species, increasing cell viability and protects mito-
chondrial membrane potential (ΔΨm) [27]. Indeed, previous studies 
confirmed this and indicated that tibolone reduces TNF-α [51], IL1 and 
IL6 in rats. 
Although IL6 is a cytokine with pleiotropic properties and its 
detection is an indicator of inflammation in TBI, Penkowa et al. (2003) 
identified that during an acute TBI, IL6 has a neuroprotective role [55]. 
In a similar way, Winter et al. (2004) showed that IL6 is produced 
following acute stage TBI and is correlated with an improved recovery 
rate indicating protective properties [56]. Further, IL6KO mice produce 
a worse behavioural recovery than controls in the short term following a 
TBI [57]. However, it is important to note that IL6 is used as a correlative 
marker of outcome of TBI where plasma levels of IL6 in TBI patients 
have been used to predict complications and prognosis [58]. Here higher 
concentrations of IL6 may indicate worse outcome, this may be due to 
increased pro-inflammatory processes or an increased expression of IL6 
for neuroprotection under more severe instances of TBI. Given that IL6 
and oxidative stress increase following a TBI, exploration of the appli-
cation of tibolone for therapeutic use has strong potential. TBI initiated a 
series of pathophysiological changes such as reducing blood flow to the 
injury which can contribute to the development of an increased oxida-
tive stress profile in the brain [59]. This can generate reactive oxygen 
species which cause mitochondrial dysfunction which damages proteins 
and the phospholipid membrane of neurons and glia. Following oxida-
tive stress may initiate the release of cytokines which then may stimulate 
glial activity whereby the action of these three factors are all involved in 
the pathogenesis of TBI [60]. 
4.3. In silico molecular simulation indicates binding interaction of 
tibolone metabolites and IL6 
Both tibolone and IL6 regulate many of the genes responsible for 
inflammation, proliferation and apoptosis regulation. These mecha-
nisms are important factors in a number of diseases and regulating these 
cellular processes are critical to the management of TBI [61]. Our 
analysis has identified that tibolone and IL6 both associate with 
protein-protein interactions in these processes, meaning the neuro-
protective role of tibolone could be accentuated by an interaction be-
tween tibolone metabolites with IL6 and associated pathways. The IL6 
receptor complex consists of the IL6R subunit to which IL6 binds to 
forming a complex which then associated with the gp130 subunit which 
initiates signalling. For instance, IL6 binds to the IL6R – gp130 receptor 
complex which activates downstream JAK-STAT and PI-3 kinase/AKT, 
two pathways involved heavily in the regulation of cell survival, pro-
liferation and autophagy [62,63]. IL6 may promote cellular prolifera-
tion and inhibit apoptosis by JAK-STAT3 signalling pathways in some 
cells [62]. There are two specific regions of IL6 important for function. 
Firstly, the amino acid residues 77–95 (region 2c) are involved in the 
binding of IL6 to the IL6R receptor complex, secondly, the amino-acid 
residues 43–55 (region 2a) is vital for IL6R dependent activation of 
gp310. Interestingly, our in silico analysis revealed that tibolone me-
tabolites may form complexes with IL6 (Fig. 6). Of particular interest 
were interactions with the active sites of binding where 3α-OH tibolone 
may interact with the gp310 binding site at Lys86 and Glu93, 3β-OH 
tibolone might interact with the IL6R binding site at Lys46 and Δ4-OH 
tibolone with the IL6R binding site at Lys46 and Met49. The interaction 
of tibolone metabolites with IL6 amino acid residues vital for binding 
with IL6R and gp130 indicates a potential mechanism of action by which 
tibolone may interact with IL6 and IL6 signalling. 
5. Conclusions 
Neuroinflammation is a coordinated response mechanism in the 
central nervous system, and a clinical common feature in TBI’s acute and 
chronic stages. One consequence of this inflammation lies in the acti-
vation of glial cells, which together with other cellular components of 
the CNS and the immune system, have an important role in modulating 
the neuroinflammatory response. During TBI, cells produce and respond 
to molecular signals that in most cases lead to dichotomous processes, 
which can promote the intensification of damage or contribute to repair. 
Activated astrocytes, for example, are known to participate in the pro-
duction and response to soluble mediators such as the cytokine IL6, in 
addition to regulating oxidative stress and maintaining the integrity and 
function of the blood-brain barrier. Identifying the signalling mecha-
nisms involved in the pathology of TBI is deemed essential to implement 
more accurate and precise treatments, because there is no specific 
treatment able to reduce the burden that TBI brings to patients. Using 
network pharmacology, in this study we report the proteins that may 
participate in the neuroprotective actions of tibolone in TBI. By acting 
on cell proliferation, regulation of inflammation and apoptotic mecha-
nisms tibolone has been shown to be promising for drug repurpose in 
TBI. Because the regulation of these processes involves IL6 sigalling, we 
also suggest IL6 as being an essential cellular node involved in tibolone 
actions over TBI pathology. 
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J. González, A. Sahebkar, L.M. Garcia-Segura, G.E. Barreto, Astrocytes mediate 
protective actions of estrogenic compounds after traumatic brain injury, 
Neuroendocrinology 108 (2) (2019) 142–160. 
[5] E. Acaz-Fonseca, M. Avila-Rodriguez, L.M. Garcia-Segura, G.E. Barreto, Regulation 
of astroglia by gonadal steroid hormones under physiological and pathological 
conditions, Prog. Neurobiol. 144 (2016) 5–26. 
[6] H.-L. Oscar, B.-J. Eliana, V. Echeverria, A. Ghulam, A. Sahebkar, G.-SL Miguel, R.C. 
Melcangi, G.E. Barreto, 2019. Lipotoxicity, neuroinflammation, glial cells and 
oestrogenic compounds. 
[7] F. Liu, M. Day, L.C. Muniz, D. Bitran, R. Arias, R. Revilla-Sanchez, S. Grauer, 
G. Zhang, C. Kelley, V. Pulito, Activation of estrogen receptor-β regulates 
A.J. McGovern and G.E. Barreto                                                                                                                                                                                                            
Biomedicine & Pharmacotherapy 140 (2021) 111769
8
hippocampal synaptic plasticity and improves memory, Nat. Neurosci. 11 (3) 
(2008) 334–343. 
[8] L.M. Garcia-Segura, I. Azcoitia, L.L. DonCarlos, Neuroprotection by estradiol, Prog. 
Neurobiol. 63 (1) (2001) 29–60. 
[9] D. Garcia-Ovejero, I. Azcoitia, L.L. Doncarlos, R.C. Melcangi, L.M. Garcia-Segura, 
Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones, 
Brain Res. Rev. 48 (2) (2005) 273–286. 
[10] O. Rabbani, K.S. Panickar, G. Rajakumar, M.A. King, N. Bodor, E.M. Meyer, J. 
W. Simpkins, 17 β-estradiol attenuates fimbrial lesion-induced decline of ChAT- 
immunoreactive neurons in the rat medial septum, Exp. Neurol. 146 (1) (1997) 
179–186. 
[11] K.J. Jones, T.E. Durica, S.K. Jacob, Gonadal steroid preservation of central synaptic 
input to hamster facial motoneurons following peripheral axotomy, J. Neurocytol. 
26 (4) (1997) 257–266. 
[12] L. Tanzer, K.J. Jones, Gonadal steroid regulation of hamster facial nerve 
regeneration: effects of dihydrotestosterone and estradiol, Exp. Neurol. 146 (1) 
(1997) 258–264. 
[13] I. Azcoitia, G.E. Barreto, L.M. Garcia-Segura, Molecular mechanisms and cellular 
events involved in the neuroprotective actions of estradiol. Analysis of sex 
differences, Front. Neuroendocr. 55 (2019), 100787, https://doi.org/10.1016/j. 
yfrne.2019.100787. 
[14] L.M. Garcia-Segura, P. Cardona-Gomez, F. Naftolin, J.A. Chowen, Estradiol 
upregulates Bcl-2 expression in adult brain neurons, Neuroreport 9 (4) (1998) 
593–597, https://doi.org/10.1097/00001756-199803090-00006. 
[15] Z.-J. Wang, C.-L. Liang, G.-M. Li, C.-Y. Yu, M. Yin, Neuroprotective effects of 
arachidonic acid against oxidative stress on rat hippocampal slices, Chem. Biol. 
Interact. 163 (3) (2006) 207–217. 
[16] G. Barreto, S. Veiga, I. Azcoitia, L.M. Garcia-Segura, D. Garcia-Ovejero, 
Testosterone decreases reactive astroglia and reactive microglia after brain injury 
in male rats: role of its metabolites, oestradiol and dihydrotestosterone, Eur. J. 
Neurosci. 25 (10) (2007) 3039–3046. 
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[30] Y. González-Giraldo, A.V. Garzón-Benitez, D.A. Forero, G.E. Barreto, TERT 
inhibition leads to reduction of IL-6 expression induced by palmitic acid and 
interferes with the protective effects of tibolone in an astrocytic cell model, 
J. Neuroendocrinol. 31 (8) (2019) 12768. 
[31] D. Osorio, A. Pinzón, C. Martín-Jiménez, G.E. Barreto, J. González, Multiple 
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